Biogen closed 2022 with a better-than-expected fourth quarter, as more cost cutting helped counter sales declines for so...

Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to...

Shares of Biogen started tumbling early Wednesday, a day after regulators slapped strict limitations on coverage the dru...

Biogen is slashing the price of its Alzheimer’s treatment months after the drug debuted to widespread criticism for an i...